Estrogen Patch Shows Promise For Prostate Cancer, Imperial College London Study  
8/11/2008 6:36:05 AM

NEW YORK AUG 08, 2008 (Reuters Health) - Early data from a multicenter phase II trial using transdermal estrogen patches as first-line androgen-deprivation therapy in patients with locally advanced or metastatic prostate cancer show that the Fem7 patch (Merck) substantially reduces testosterone levels, UK researchers report in the August issue of BJU International.